Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer
Authors:
- 29 November 2021
- journal article
- research article
- Published by Springer Nature in Nature Cancer
- Vol. 3 (1) , 60-74
Abstract
Despite increased overall survival rates, curative options for metastatic breast cancer remain limited. We have previously shown that metadherin (MTDH) is frequently overexpressed in poor prognosis breast cancer, where it promotes metastasis and therapy resistance through its interaction with staphylococcal nuclease domain-containing 1 (SND1). Through genetic and pharmacological targeting of the MTDH–SND1 interaction, we reveal a key role for this complex in suppressing antitumor T cell responses in breast cancer. The MTDH–SND1 complex reduces tumor antigen presentation and inhibits T cell infiltration and activation by binding to and destabilizing Tap1/2 messenger RNAs, which encode key components of the antigen-presentation machinery. Following small-molecule compound C26-A6 treatment to disrupt the MTDH–SND1 complex, we showed enhanced immune surveillance and sensitivity to anti-programmed cell death protein 1 therapy in preclinical models of metastatic breast cancer, in support of this combination therapy as a viable approach to increase immune-checkpoint blockade therapy responses in metastatic breast cancer.Keywords
Funding Information
- U.S. Department of War (BC151403)
This publication has 55 references indexed in Scilit:
- MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor CellsJNCI: Journal of the National Cancer Institute, 2013
- Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockadeExpert Review of Anticancer Therapy, 2012
- Dynamics of Major Histocompatibility Complex Class I Association with the Human Peptide-loading ComplexJournal of Biological Chemistry, 2012
- Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycanBreast Cancer Research, 2012
- Cytoplasmic Metadherin (MTDH) Provides Survival Advantage under Conditions of Stress by Acting as RNA-binding ProteinJournal of Biological Chemistry, 2012
- Treating cancer with genetically engineered T cellsTrends in Biotechnology, 2011
- Identification of Staphylococcal Nuclease Domain-containing 1 (SND1) as a Metadherin-interacting Protein with Metastasis-promoting FunctionsJournal of Biological Chemistry, 2011
- Structural arrangement of the transmission interface in the antigen ABC transport complex TAPProceedings of the National Academy of Sciences, 2009
- MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast CancerCancer Cell, 2009
- Generation of a functional mammary gland from a single stem cellNature, 2006